Sat.Jun 25, 2022 - Fri.Jul 01, 2022

article thumbnail

Social Media is dangerous for patients

World of DTC Marketing

Suppose you’re on Facebook or Instagram, and Meta has determined you may be interested in cancer treatments. In that case, you may have seen an ad for a dangerous cancer treatment, or one of the 20 or so others recently running from the CHIPSA hospital in Mexico near the US border, all of which are publicly listed in Meta’s Ad Library. They are part of a pattern on Facebook of ads that make misleading or false health claims targeted at cancer patients.

Media 228
article thumbnail

Journal Citation Reports 2022: COVID-19 research continues to drive increased citation impact

Clarivate

Today we release the 2022 update to the annual Journal Citation Reports (JCR). This year’s release demonstrates the enormous impact the COVID-19 pandemic has had on scholarly publishing. We also identify and define a new type of anomalous citation behavior: self-stacking. The annual JCR release enables the research community to evaluate the world’s high-quality academic journals using a range of indicators, descriptive data and visualizations.

Medicine 141
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

PharmaVoice

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

134
134
article thumbnail

Why obesity intervention needs to be a bigger part of chronic disease care

MedCity News

Obese patients are more at risk for diabetes, cardiovascular disease, certain cancers and mortality than patients who maintain a healthy weight, and obese patient who develop these chronic conditions usually have more complications. That is why providers and payers must integrate more weight loss strategies in chronic condition care, panelists argued at a Tuesday panel hosted by the Chamber of Commerce.

Patients 126
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Takeda’s Peter Schnack on digital’s role in driving innovation and improving patient outcomes

Dominic Tyer

Why digital and data should be available to everybody in a pharma commercial organisation

Patients 130
article thumbnail

Smart Jumpsuit Tracks Motor Development in Children

Medgadget

Researchers at the University of Helsinki in Finland created a smart jumpsuit that can track toddler movements. The idea is to closely monitor motor development and identify any issues early, allowing for earlier interventions. Issues with motor development can be related to wider neurodevelopmental problems, and so tracking a young child’s activity can provide a window into their overall development.

More Trending

article thumbnail

Metaverse in healthcare

MedCity News

Dr. Mona Flores, Global Head of Medical AI at Nvidia, will deliver the keynote talk kicking off the MedCity INVEST Digital Health conference, scheduled for Wednesday, September 28, in Dallas and presented in collaboration with Health Wildcatters. Register today.

article thumbnail

The Creative Floor Awards Announce the 2022 Finalists

PM360

The Creative Floor Healthcare Awards has announced this year’s finalists. Entries have come from the U.S., South America, UK, EU, Australia, Japan, New Zealand, Philippines, Singapore, China, and the Middle East. The finalist companies include: Shaheed Peera, Founder of the Creative Floor Healthcare Awards said: “From the bottom of my heart and everyone at The Creative Floor, thank you to everyone who supports this amazing award show.

article thumbnail

FDA rejection of Spero’s tebipenem ‘raises resistance threat’

pharmaphorum

The FDA’s decision not to approve Spero Therapeutics’ oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic resistance, according to a GlobalData analyst. The FDA delivered a blow to Spero’s hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.

FDA 112
article thumbnail

Magazine-How delays derailed Covid-19 vaccination in Africa

Pharmaceutical Technology

The latest issue of Pharma Technology Focus is out now. Read it for free on all devices. Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. Global trends indicate that initially, a slow supply did not allow African countries, in particular, to stay on pace to meet this target, and now vaccination rates have even begun to slow down.

Pharma 110
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Magnetic Steering System for Guidewires

Medgadget

Percutaneous coronary intervention is an incredibly useful technique to minimally invasively investigate and treat cardiac issues, such as blockages in the coronary arteries, but it requires a significant amount of skill to perform safely and effectively. Manipulating a guidewire through the tortuous vasculature is not for the faint hearted, with the possibility of perforating a vessel always near.

article thumbnail

Seven Strategies for Succeeding as a Small Fish in a Big Pond

PM360

The biotech sector has seen its fair share of unsettling dynamics over the past 18 months. From unprecedented growth to wavering confidence from investors, emerging biotech organizations have had to become both resourceful and creative. At the same time, Big Pharma and the medical device firms have turned around COVID-19 diagnostics, vaccines, and therapeutics at a stunningly impressive pace, in part due to decades of investment in the people and the scientific advances they pioneer.

Medicine 105
article thumbnail

GSK hepatitis B hope bepirovirsen heads for phase 3 test

pharmaphorum

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a “functional cure” for the widespread disease. Interim results from the phase 2b B-Clear showed that bepirovirsen reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks’ treatment to below the lower limit of detection in people with chronic hepatitis B, raising hopes

Sales 110
article thumbnail

AI hiring levels in the pharmaceutical industry rose in May 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for AI related positions kept relatively steady in May 2022 compared with the equivalent month last year, with 39.3% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 39% of companies who were hiring for AI related jobs a year ago but a decrease compared to the figure of 43.6% in April 2022.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Astellas pays Sutro Bio $90M to partner on cancer drugs that make cold tumors hot

MedCity News

Astellas Pharma has a new partner in the R&D of a type of cancer drug called an antibody drug conjugate (ADC). The Japanese pharma company reached across the Pacific Ocean to collaborate with Sutro Biopharma in a bet that Bay Area-based firm’s technology can deliver more powerful ADCs.

Biopharma 105
article thumbnail

How should cleaning validation sampling locations be chosen?

European Pharmaceutical Review

A recent paper outlines a process that can be used to select and document worst-case sampling locations to validate cleaning processes. The article, published in the Journal of Validation Technology ( JVT ), presents the case study of a company undergoing an investigation and developing a strategy for identifying worst-case sampling locations on equipment, after a regulatory auditor asked for such a rationale and no written documentation could be provided.

article thumbnail

Merck launches accelerator programme for AI startups

pharmaphorum

Merck & Co is looking for startup companies applying artificial intelligence , machine-learning and other digital approaches to drug discovery and development for a new accelerator programme. The big pharma – known as MSD outside North America – is initially offering support to 12 companies though the newly-formed Merck Digital Sciences Studio (MDSS) and is now taking applications from would-be participants.

Pharma 108
article thumbnail

Pfizer seeks approval from US FDA for Covid-19 treatment

Pharmaceutical Technology

Pfizer has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for Paxlovid (nirmatrelvir tablets and ritonavir tablets) to treat Covid-19 patients at increased disease progression risk. An inhibitor of SARS-CoV-2 main protease (Mpro), Paxlovid is intended to be given orally. Due to the oral form, the therapy can be prescribed in the early infection stage to avert severe illness.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review

MedCity News

Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.

FDA 102
article thumbnail

Global Blood Therapeutics: driving innovation in sickle cell disease

European Pharmaceutical Review

Sickle cell disease – a rare, yet prevalent, genetic disease in Europe. Sickle cell disease (SCD) is a devastating, lifelong blood disorder that occurs when someone inherits sickle cell genes from both parents. 1 It affects haemoglobin, a protein carried by red blood cells that delivers oxygen throughout the body. 2 SCD predominantly affects those whose ancestors are from sub-Saharan Africa but is also common in people of Hispanic, South Asian, Southern European and Middle Eastern ancestry. 3 Wh

article thumbnail

Study exposes lack of diversity in US cancer trials

pharmaphorum

Almost half (48%) of cancer clinical trials in the US have no Hispanic or Latin American subjects, and 42% have no black patients, according to a diversity analysis focusing on thousands of studies conducted in the past 15 years. The analysis – from a dataset that spans more than half a million patients – reveals once again the lack of inclusivity in clinical research, which undermines the ability of clinical trials to generate results that reflect the real-world situation in US cancer treatmen

article thumbnail

Terumo and GenCure sign agreement for cell and gene therapies

Pharmaceutical Technology

Terumo Blood and Cell Technologies and BioBridge Global subsidiary, GenCure, have entered a new partnership agreement to expand and integrate cell and gene therapy manufacturing solutions. In a bid to meet the growing demand for automated and closed smart systems across the cell and gene therapy (CGT) industry, the companies entered the deal to merge technologies and capabilities.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

How health systems can successfully manage and grow their provider networks with an EHR

MedCity News

Against the backdrop of the pandemic, the preferences and expectations of healthcare consumers have […].

article thumbnail

Pursuing new paths in targeted protein degradation drug development

European Pharmaceutical Review

DRUG DEVELOPMENT based on targeted protein degradation (TPD) has progressed rapidly since the publication in 2015 of three landmark papers 1-3 that highlighted important early-stage breakthroughs with drug-like molecules in this area of research. Since that time, the field has advanced to the point where there are now more than two dozen companies dedicated to working on the development of TPD drugs, some of which have advanced to later-stage clinical development.

article thumbnail

Bayer launches digital AI platform for radiology specialists

pharmaphorum

Bayer has stepped up the digital capabilities of its radiology business with the launch of artificial intelligence-based apps for X-ray, MRI and CT imaging. The cloud-hosted platform – called Calantic Digital Solutions – has tools to help radiologists detect and quantify disease lesions in medical images and select patients for treatment in order of priority, improving their productivity.

Medical 102
article thumbnail

Astellas and Sutro partner to develop immunostimulatory ADCs

Pharmaceutical Technology

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule. It can potentially enhance the anti-cancer effect.

Biopharma 105
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Bayer, Amgen join $120M financing for startup aiming to expand genetic meds delivery

MedCity News

In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.

Medicine 101
article thumbnail

Healthier Together and philanthropic ventures in tropical disease

European Pharmaceutical Review

Europe’s Healthier Together initiative. The European Commission (EC) has launched the Healthier Together: EU Non-communicable diseases (NCDs) initiative to support EU Member States in reducing the burden of NCDs by addressing the leading causes of avoidable premature death in Europe and improving citizens’ health and well-being. The €156 million initiative identifies effective actions and the available legal and financial supporting tools across five main areas: cardiovascular diseases, di

article thumbnail

Q&A With Anastasiia Kamenska, director of corporate strategy, Novartis

PharmExec

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies.

article thumbnail

WHO’s new hepatitis C guidelines a step forward in reaching those in need

Pharmaceutical Technology

Last Friday, the World Health Organization (WHO) launched updated guidelines for the treatment of hepatitis C , calling for testing and treatment to be delivered in peripheral and community-based facilities and integrating these with available care services. While some countries are making progress in eliminating hepatitis C, many remain challenged in reaching those affected, Dr Philippa Easterbrook, Senior Scientist at WHO’s Department of Global HIV, Hepatitis and Sexually Transmitted Infection

article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.